Globin Solutions, Inc., a biotechnology startup formed in 2017 by School of Medicine faculty members Mark T. Gladwin, Jack D. Myers, Jason J. Rose and Jesus Tejero Bravo to develop a rapidly acting antidote to carbon monoxide (CO) poisoning, in April completed a Series A funding round of more than $5 million. Tus S&T Service Group of Beijing, China, led the round with participation from UPMC Enterprises, the commercialization arm of UPMC.
The funding will support further development of the lead compound, recombinant neuroglobin. Globin Solutions is the exclusive licensee of the University-owned intellectual property.